DNB5 inhibitors constitute a distinctive and intricate chemical class characterized by their specific molecular attributes and functional behaviors. These compounds are meticulously fashioned to interact with the enzyme DNB5, a pivotal player in a myriad of biochemical processes. Within this class, the inhibitors are purposefully tailored to engage with the active site of the DNB5 enzyme, impeding its catalytic prowess through a series of strategic molecular interactions. These interactions involve precise chemical bonding, hydrogen bonding, hydrophobic interactions, and electrostatic forces, collectively orchestrating the formation of a stable and reversible complex between the inhibitor and the enzyme. The structural architecture of DNB5 inhibitors is finely crafted to harmonize with the complex three-dimensional arrangement of the enzyme's active site residues.
This tailored fit enables a remarkable level of binding affinity and selectivity, which in turn underscores the efficacy of these inhibitors in modulating DNB5 activity. The chemical diversity encompassed by the DNB5 inhibitor class is extensive, with distinct molecular scaffolds, substituents, and functional groups meticulously incorporated to optimize interactions and amplify binding potency. These inhibitors serve as valuable instruments for researchers aiming to scrutinize the functional intricacies of DNB5 across various biological contexts. By employing DNB5 inhibitors, scientists can gain insights into the enzyme's involvement in diverse biochemical pathways. The intricate dance between these inhibitors and DNB5 offers a nuanced understanding of the enzyme's role in cellular processes, which in turn contributes to the advancement of knowledge in molecular biology, enzymology, and related fields.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
ABT-199 is a BCL-2 inhibitor that binds to the BCL-2 protein, preventing its interaction with pro-apoptotic proteins. This promotes programmed cell death (apoptosis) in cancer cells, particularly in chronic lymphocytic leukemia (CLL) and other B-cell malignancies. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. It covalently binds to BTK, blocking B-cell receptor signaling and inhibiting B-cell proliferation and survival. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. It prevents repair of single-strand DNA breaks in cancer cells with defective DNA repair mechanisms (e.g., BRCA mutations), leading to their death. | ||||||
Rucaparib | 283173-50-2 | sc-507419 | 5 mg | $150.00 | ||
Rucaparib is another PARP inhibitor, similarly blocking DNA repair in cancer cells with damaged DNA repair pathways. It's indicated for ovarian cancer and certain other solid tumors associated with BRCA mutations. | ||||||
Niraparib | 1038915-60-4 | sc-507492 | 10 mg | $150.00 | ||
Niraparib, a PARP inhibitor, disrupts DNA repair processes in cancer cells with deficient repair mechanisms, causing their demise. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib, like Palbociclib, is a CDK4/6 inhibitor. It impedes cell cycle advancement in cancer cells, especially in combination with hormone receptor-positive, HER2-negative metastatic breast cancer research. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is a CDK4/6 inhibitor that restrains cell cycle progression in cancer cells, particularly when combined with endocrine therapies for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus inhibits the mechanistic target of rapamycin (mTOR) pathway, reducing cell growth and proliferation. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Enzalutamide is an androgen receptor (AR) inhibitor that interferes with AR signaling, suppressing the growth of AR-positive prostate cancer cells. | ||||||